Depomed, Inc. (NASDAQ:DEPO) today reported financial results for the first quarter ended March 31, 2010.

Revenue for the three months ended March 31, 2010 was $15.4 million compared to $9.9 million for the three months ended March 31, 2009. The 56% increase in revenue year-over-year was primarily attributable to a $5.8 million increase in Glumetza product sales.

Operating expenses for the three months ended March 31, 2010 were $17.6 million compared to $19.0 million for the three months ended March 31, 2009. The decrease in operating expenses was primarily attributable to $4.8 million decrease in research and development expenses and a $0.9 million decrease in other selling, general and administrative expenses, partially offset by a $4.3 million increase in promotion fee expense related to the company’s promotion agreement for Glumetza ® (extended release metformin hydrochloride tablets) with Santarus, Inc. due to the increase in product sales.

Stock-based compensation expense was $0.5 million for the three months ended March 31, 2010 as compared to $0.7 million for the three months ended March 31, 2009.

Net loss for the three months ended March 31, 2010 was $3.8 million, or $0.07 per share, compared to net loss of $10.2 million, or $0.20 per share, for the three months ended March 31, 2009.

Cash, cash equivalents and marketable securities were $71.5 million as of March 31, 2010 compared to $81.8 million as of December 31, 2009.

“In the first quarter, we made significant advances in our development programs in DM-1796 for postherpetic neuralgia and Serada TM for menopausal hot flashes. Abbott Products Inc. filed an NDA for DM-1796 in March, and we look forward to the FDA’s acceptance of the NDA for filing later this quarter. We received encouraging guidance on Serada’s development program in the quarter, and expect to initiate one additional Phase 3 clinical trial very soon,” noted Carl A. Pelzel, president and chief executive officer of Depomed.

First Quarter 2010 Highlights
  • Commented on FDA guidance and plans for one additional Phase 3 clinical trial evaluating non-hormonal therapy for menopausal hot flashes (January 2010).
  • Announced receipt of a $500,000 milestone payment from Covidien for the development of a second formulation (January 2010).
  • Announced allowance of a U.S. patent covering gastric retentive Gabapentin dosage forms (February 2010).
  • Announced submission of a New Drug Application for DM-1796 postherpetic neuralgia (March 2010).

Conference Call

Depomed will host a conference call today, Thursday, April 29, beginning at 5:00 p.m. ET, 2:00 p.m. PT to discuss its results. The conference call will be available via a live webcast on the investor relations section of Depomed’s website at Access the website 15 minutes prior to the start of the call to download and install any necessary audio software. An archived webcast replay will be available on the Company’s website for three months.

About Depomed

Depomed, Inc. is a specialty pharmaceutical company with one product candidate through Phase 3 clinical development, another in Phase 3 clinical development, two approved products on the market and other product candidates in its early stage pipeline. Product candidate DM-1796 has completed Phase 3 clinical development and has been licensed to Abbott Products Inc. A New Drug Application for DM-1796 was filed with the FDA in the first quarter of 2010. Product candidate Serada TM is in Phase 3 clinical development for menopausal hot flashes. GLUMETZA ® (metformin hydrochloride extended release tablets) is approved for use in adults with type 2 diabetes and promoted by Santarus, Inc. in the United States. Depomed formulates its products and product candidates with its proven, proprietary Acuform ® drug delivery technology, which is designed to improve existing oral medications, allowing for extended, controlled release of medications to the upper gastrointestinal tract. Benefits of Acuform-enhanced pharmaceuticals include the convenience of once-daily administration, improved treatment tolerability and enhanced compliance and efficacy. Additional information about Depomed may be found on its website,

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995.

The statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties including, but not limited to, those related to our clinical development programs; our research and development efforts, including pre-clinical and clinical testing; regulation by the FDA and other government agencies; the timing of regulatory applications and product launches; and other risks detailed in the company's Securities and Exchange Commission filings, including the company's Annual Report on Form 10-K. You are cautioned not to place undue reliance on these forward-looking statements which speak only as of the date hereof. The company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.



(in thousands, except share and per share amounts)

Three Months Ended March 31,

2010   2009
Product sales $ 12,601 $ 6,840
Royalties 88 464
License and milestone revenue 2,671 2,568
Total revenues 15,360 9,872
Costs and expenses:
Cost of sales 1,481 1,032
Research and development expense 5,187 10,021
Selling, general and administrative expense:
Promotion fee expense 8,879 4,544
Other selling, general and administrative 3,550 4,458
Total selling, general and administrative expense 12,429 9,002
Total costs and expenses 19,097 20,055
Loss from operations (3,737 ) (10,183 )
Other income (expense):
Interest and other income 94 314
Interest expense (183 ) (285 )
Total other income (expense) (89 ) 29
Net loss before income taxes (3,826 ) (10,154 )
Provision for income taxes (1 ) (1 )
Net loss $ (3,827 ) $ (10,155 )
Basic and diluted net loss per share $ (0.07 ) $ (0.20 )
Shares used in computing basic and diluted net loss per share 52,298,726 51,207,540



(in thousands, except share amounts)
March 31, December 31,
2010 2009
(Unaudited) (1)
Current assets:
Cash and cash equivalents

7,424 $ 26,821
Marketable securities 51,527 42,922
Accounts receivable 6,276 4,933
Inventories 2,760 2,565
Prepaid and other current assets 2,634 1,185
Total current assets 70,621 78,426
Marketable securities, long-term 12,524 12,016
Property and equipment, net 871 942
Other assets 197 197
$ 84,213 $ 91,581
Current liabilities:
Accounts payable and accrued liabilities 14,452 15,222
Deferred product sales 1,594 1,635
Deferred license revenue 11,159 11,184
Other current liabilities 425 414
Current portion of long-term debt 3,859 3,747
Total current liabilities 31,489 32,202
Deferred license revenue, non-current portion 38,660 41,306
Long-term debt, net of current portion 1,160 2,170
Other long-term liabilities 143 177
Shareholders’ equity:
Preferred stock, no par value, 5,000,000 shares authorized; Series A convertible preferred stock, 25,000 shares designated, 18,158 shares issued and surrendered, and zero shares outstanding at March 31, 2010 and December 31, 2009

Common stock, no par value, 100,000,000 shares authorized; 52,354,402 and 52,200,358 shares issued and outstanding at March 31, 2010 and December 31, 2009, respectively

188,756 187,895
Accumulated deficit (176,029 ) (172,202 )
Accumulated other comprehensive gain 34 33
Total shareholders’ equity 12,761 15,726
$ 84,213 $ 91,581


(1) Derived from the audited financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2009.

Copyright Business Wire 2010